News

European Regulators Grant Orphan Drug Status to Protalix’s PRX-102 for Fabry Disease

The European Commission has granted Protalix BioTherapeutics’ experimental treatment PRX-102 (pegunigalsidase alfa) Orphan Drug Designation for the treatment of Fabry disease, the company recently announced. The decision follows a European Medicines Agency (EMA) recommendation in November 2017, which stated the therapy may be of “significant benefit” to Fabry…